Bicara Therapeutics Inc. (BCAX) vs Puma Biotechnology, Inc. (PBYI)
- Bicara Therapeutics Inc. BCAX 8.83 −1.45%
- Puma Biotechnology, Inc. PBYI 10.71 +4.79%
Bicara Therapeutics Inc. and Puma Biotechnology, Inc. are both Biotechnology companies. Bicara Therapeutics Inc. is the larger, with a market value of $592.9M against $527.6M — 1.1× the size. Bicara Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Puma Biotechnology, Inc. trades at 18.9×. Puma Biotechnology, Inc. has the higher net margin (11.6% vs 0.00%) and the higher return on invested capital (42.6% vs 0.00%). Across the 12 metrics below, Puma Biotechnology, Inc. leads on 9 and Bicara Therapeutics Inc. on 3.
Valuation
Profitability
| Metric | BCAX | PBYI | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 74.83% | 65.59% |
| Operating margin | 0.00% | 13.16% | 0.00% |
| Net margin | 0.00% | 11.55% | 0.00% |
| Free cash flow margin | 0.00% | 17.79% | 0.00% |
| Return on equity | (41.01%) | 21.97% | (51.96%) |
| Return on assets | (38.38%) | 13.78% | (46.06%) |
| Return on invested capital | 0.00% | 42.61% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack